Why Gilead Sciences Is Now A Hold (Rating Upgrade)

Gilead Sciences, Inc. once again demonstrated strong performance of Trodelvy, Livdelzi, and Yeztugo. This "trio" generated $701 million in revenue for Gilead in Q1, up 110.5% quarter-on-quarter. However, Gilead's cell therapy franchise is once again struggling, with sales of Yescarta and Tecartus falling 12.3% YoY....

Seeking Alpha - 5/21/2026 9:46:33 AM More News for GILD
Stock Analysis for GILD
Related Stocks: